Base de dados : MEDLINE
Pesquisa : D20.215.894.899 [Categoria DeCS]
Referências encontradas : 21827 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 2183 ir para página                         

  1 / 21827 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28457675
[Au] Autor:Wichgers Schreur PJ; van Keulen L; Kant J; Kortekaas J
[Ad] Endereço:Department of Virology, Wageningen Bioveterinary Research, Lelystad, The Netherlands. Electronic address: paul.wichgersschreur@wur.nl.
[Ti] Título:Four-segmented Rift Valley fever virus-based vaccines can be applied safely in ewes during pregnancy.
[So] Source:Vaccine;35(23):3123-3128, 2017 05 25.
[Is] ISSN:1873-2518
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Rift Valley fever virus (RVFV) causes severe and recurrent outbreaks on the African continent and the Arabian Peninsula and continues to expand its habitat. This mosquito-borne virus, belonging to the genus Phlebovirus of the family Bunyaviridae contains a tri-segmented negative-strand RNA genome. Previously, we developed four-segmented RVFV (RVFV-4s) variants by splitting the M-genome segment into two M-type segments each encoding one of the structural glycoproteins; Gn or Gc. Vaccination/challenge experiments with mice and lambs subsequently showed that RVFV-4s induces protective immunity against wild-type virus infection after a single administration. To demonstrate the unprecedented safety of RVFV-4s, we here report that the virus does not cause encephalitis after intranasal inoculation of mice. A study with pregnant ewes subsequently revealed that RVFV-4s does not cause viremia and does not cross the ovine placental barrier, as evidenced by the absence of teratogenic effects and virus in the blood and organs of the fetuses. Altogether, these results show that the RVFV-4s vaccine virus can be applied safely in pregnant ewes.
[Mh] Termos MeSH primário: Febre do Vale de Rift/prevenção & controle
Vírus da Febre do Vale do Rift/genética
Vírus da Febre do Vale do Rift/imunologia
Doenças dos Ovinos/prevenção & controle
Vacinas Virais/administração & dosagem
Vacinas Virais/efeitos adversos
[Mh] Termos MeSH secundário: Animais
Anticorpos Neutralizantes/sangue
Anticorpos Antivirais/sangue
Encefalite Viral/etiologia
Encefalite Viral/veterinária
Feminino
Genoma Viral/genética
Genoma Viral/imunologia
Camundongos
Gravidez
Febre do Vale de Rift/virologia
Vírus da Febre do Vale do Rift/química
Ovinos
Carneiro Doméstico/imunologia
Teratogênios
Vacinas Atenuadas/administração & dosagem
Vacinas Atenuadas/efeitos adversos
Vacinas Atenuadas/imunologia
Vacinas Virais/imunologia
Viremia/prevenção & controle
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antibodies, Neutralizing); 0 (Antibodies, Viral); 0 (Teratogens); 0 (Vaccines, Attenuated); 0 (Viral Vaccines)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE


  2 / 21827 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28453838
[Au] Autor:Lindesmith LC; Mallory ML; Jones TA; Richardson C; Goodwin RR; Baehner F; Mendelman PM; Bargatze RF; Baric RS
[Ad] Endereço:Department of Epidemiology, University of North Carolina, Chapel Hill, NC, USA.
[Ti] Título:Impact of Pre-exposure History and Host Genetics on Antibody Avidity Following Norovirus Vaccination.
[So] Source:J Infect Dis;215(6):984-991, 2017 03 15.
[Is] ISSN:1537-6613
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Background: Development of high avidity, broadly neutralizing antibodies (Abs) is a priority after vaccination against rapidly evolving, widely disseminated viruses like human norovirus. After vaccination with a multivalent GI.1 and GII.4c norovirus virus-like particle (VLP) vaccine candidate adjuvanted with alum and monophosphoryl lipid A (MPL), blockade Ab titers peaked early, with no increase in titer following a second vaccine dose. Methods: Blockade Ab relative avidity was evaluated by measuring the slope of blockade Ab neutralization curves. Results: Blockade Ab avidity to the GI.1 vaccine component peaked at day 35 (7 days after dose 2). Avidities to heterotypic genogroup I VLPs were not sustained at day 35 after vaccination or GI.1 infection, as measured from archived sera. Only secretor-positive participants maintained high avidity blockade Ab to GI.1 at day 180. Avidity to the GII.4c vaccine component peaked at day 7, remained elevated through day 180, and was not secretor dependent. Avidity to an immunologically novel GII.4 strain VLP correlated with preexisting Ab titer to an ancestral strain Epitope A. Conclusions: Host genetics and pre-exposure history shape norovirus vaccine Ab responses, including blockade Ab avidity. Avidity of potentially neutralizing Ab may be an important metric for evaluating vaccine responses to highly penetrant viruses with cross-reactive serotypes.
[Mh] Termos MeSH primário: Afinidade de Anticorpos
Infecções por Caliciviridae/prevenção & controle
Vacinas de Partículas Semelhantes a Vírus/uso terapêutico
Vacinas Virais/uso terapêutico
[Mh] Termos MeSH secundário: Adjuvantes Imunológicos/administração & dosagem
Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Anticorpos Neutralizantes/sangue
Anticorpos Antivirais/sangue
Infecções por Caliciviridae/genética
Reações Cruzadas
Método Duplo-Cego
Epitopos/imunologia
Feminino
Seres Humanos
Masculino
Meia-Idade
Norovirus
Estados Unidos
Vacinação
Vacinas de Partículas Semelhantes a Vírus/administração & dosagem
Vacinas Virais/administração & dosagem
Adulto Jovem
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE I; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Adjuvants, Immunologic); 0 (Antibodies, Neutralizing); 0 (Antibodies, Viral); 0 (Epitopes); 0 (Vaccines, Virus-Like Particle); 0 (Viral Vaccines)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.1093/infdis/jix045


  3 / 21827 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28449719
[Au] Autor:Bongard N; Lapuente D; Windmann S; Dittmer U; Tenbusch M; Bayer W
[Ad] Endereço:Institute for Virology, University Hospital Essen, University Duisburg-Essen, Virchowstr. 179, 45147, Essen, Germany.
[Ti] Título:Interference of retroviral envelope with vaccine-induced CD8 T cell responses is relieved by co-administration of cytokine-encoding vectors.
[So] Source:Retrovirology;14(1):28, 2017 Apr 27.
[Is] ISSN:1742-4690
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Retroviral envelope (Env) proteins are known to exhibit immunosuppressive properties, which become apparent not only in retroviral infections, but also in gene-based immunizations using retroviral immunogens, where envelope interferes with the induction of CD8 T cell responses towards another, simultaneously or subsequently delivered, immunogen. RESULTS: In the Friend retrovirus mouse model, immunization with a plasmid encoding the Friend murine leukemia virus (F-MuLV) Leader-Gag protein resulted in induction of a strong GagL -specific CD8 T cell response, while the response was completely abrogated by co-immunization with an F-MuLV Env-encoding plasmid. In order to overcome this interference of retroviral envelope, we employed plasmids encoding the cytokines interleukin (IL) 1ß, IL2, IL12, IL15, IL21, IL28A or granulocyte-macrophage colony-stimulating factor (GM-CSF) as genetic adjuvants. Co-application of plasmids encoding IL2, IL12, IL21, IL28A and especially GM-CSF rescued the induction of GagL -specific CD8 T cells in mice vaccinated with FV Leader-Gag and Env. Mice that were immunized with plasmids encoding Leader-Gag and Env and the cytokines IL1ß, IL12, IL15, IL28A or GM-CSF, but not Leader-Gag and Env without any cytokine, showed significantly reduced viral loads upon a high-dose Friend virus challenge infection. CONCLUSIONS: Our data demonstrate the potency of cytokine-encoding vectors as adjuvants and immune modulators in composite vaccines for anti-retroviral immunization.
[Mh] Termos MeSH primário: Linfócitos T CD8-Positivos/imunologia
Citocinas/genética
Vírus da Leucemia Murina de Friend/imunologia
Vacinas de DNA/imunologia
Proteínas do Envelope Viral/imunologia
Vacinas Virais/imunologia
[Mh] Termos MeSH secundário: Adjuvantes Imunológicos
Animais
Citocinas/imunologia
Feminino
Vírus da Leucemia Murina de Friend/genética
Produtos do Gene gag/genética
Produtos do Gene gag/imunologia
Vetores Genéticos
Imunização
Imunomodulação
Interleucina-15/genética
Interleucina-15/imunologia
Interleucina-2/genética
Interleucina-2/imunologia
Camundongos
Camundongos Endogâmicos BALB C
Plasmídeos
Infecções por Retroviridae/imunologia
Vacinas de DNA/administração & dosagem
Proteínas do Envelope Viral/genética
Proteínas do Envelope Viral/metabolismo
Carga Viral
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adjuvants, Immunologic); 0 (Cytokines); 0 (Gene Products, gag); 0 (Interleukin-15); 0 (Interleukin-2); 0 (Vaccines, DNA); 0 (Viral Envelope Proteins); 0 (Viral Vaccines)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.1186/s12977-017-0352-7


  4 / 21827 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29374509
[Au] Autor:Jin J; Park C; Cho SH; Chung J
[Ad] Endereço:Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine, Seoul 00380, Republic of Korea; Department of Biomedical Science, Seoul National University College of Medicine, Seoul 00380, Republic of Korea.
[Ti] Título:The level of decoy epitope in PCV2 vaccine affects the neutralizing activity of sera in the immunized animals.
[So] Source:Biochem Biophys Res Commun;496(3):846-851, 2018 02 12.
[Is] ISSN:1090-2104
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Viral pathogens have evolved a wide range of tactics to evade host immune responses and thus propagate effectively. One efficient tactic is to divert host immune responses toward an immunodominant decoy epitope and to induce non-neutralizing antibodies toward this epitope. Therefore, it is expected that the amount of decoy epitope in a subunit vaccine can affect the level of neutralizing antibody in an immunized animal. In this study, we tested this hypothesis by generating an antibody specific to the decoy epitope on the capsid protein of porcine circovirus type 2 (PCV2). Using this antibody, we found that two commercial vaccines contained statistically different amounts of the decoy epitope. The vaccine with lower levels of decoy epitope induced a significantly higher level of neutralizing antibody after immunization. This antibody can be used as an analytical tool to monitor the quality of a vaccine from batch to batch.
[Mh] Termos MeSH primário: Vacinas contra Adenovirus/administração & dosagem
Anticorpos Neutralizantes/imunologia
Infecções por Circoviridae/imunologia
Infecções por Circoviridae/prevenção & controle
Circovirus/imunologia
Vacinas Virais/imunologia
Vacinas Virais/toxicidade
[Mh] Termos MeSH secundário: Animais
Anticorpos Neutralizantes/sangue
Circovirus/efeitos dos fármacos
Epitopos/imunologia
Cobaias
Resultado do Tratamento
Vacinação/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Adenovirus Vaccines); 0 (Antibodies, Neutralizing); 0 (Epitopes); 0 (Viral Vaccines)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180129
[St] Status:MEDLINE


  5 / 21827 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29220358
[Au] Autor:Dorta-Estremera S; Nehete PN; Yang G; He H; Nehete BP; Shelton KA; Barry MA; Sastry KJ
[Ad] Endereço:The University of Texas MD Anderson Cancer Center, Department of Immunology, Houston, TX, United States of America.
[Ti] Título:Minimally invasive monitoring of CD4 T cells at multiple mucosal tissues after intranasal vaccination in rhesus macaques.
[So] Source:PLoS One;12(12):e0188807, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Studies in nonhuman primates (NHP) for prospective immune cell monitoring subsequent to infection and/or vaccination usually rely on periodic sampling of the blood samples with only occasional collections of biopsies from mucosal tissues because of safety concerns and practical constraints. Here we present evidence in support of cytobrush sampling of oral, rectal, and genital mucosal tissues as a minimally invasive approach for the phenotypic analyses of different T cells subsets de novo as well as prospectively after intranasal immunization in rhesus macaques. Significant percentages of viable lymphocytes were obtained consistently from both naïve and chronically SIV-infected rhesus macaques. The percentages of CD3+ T cells in the blood were significantly higher compared to those in the mucosal tissues analyzed in the naïve animals, while in the SIV+ animals the CD3+ T cells were significantly elevated in the rectal tissues, relative to all other sites analyzed. In the naïve, but not SIV+ macaques, the rectal and vaginal mucosal tissues, compared to oral mucosa and blood, showed higher diversity and percentages of CD4+ T cells expressing the HIV entry co-receptor CCR5 and mucosal specific adhesion (CD103) as well as activation (HLA-DR) and proliferation (Ki67) markers. Sequential daily cytobrush sampling from the oral, rectal, and genital mucosal tissues was performed in SIV+ animals from an ongoing study where they were administered intranasal immunization with adenoviral vectored vaccines incorporating the green fluorescent protein (GFP) reporter gene. We detected a transient increase in GFP+ CD4 T cells in only oral mucosa suggesting limited mucosal trafficking. In general, CD4+ and CD8+ T cells expressing Ki67 transiently increased in all mucosal tissues, but those expressing the CCR5, HLA-DR, and CD103 markers exhibited minor changes. We propose the minimally invasive cytobrush sampling as a practical approach for effective and prospective immune monitoring of the oral-genital mucosal tissues in NHP.
[Mh] Termos MeSH primário: Contagem de Linfócito CD4
Linfócitos T CD4-Positivos/imunologia
Macaca mulatta/imunologia
Membrana Mucosa/imunologia
Vacinas Virais/administração & dosagem
[Mh] Termos MeSH secundário: Administração Intranasal
Animais
Feminino
Citometria de Fluxo
Masculino
Síndrome de Imunodeficiência Adquirida dos Símios/imunologia
Vacinas Virais/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Viral Vaccines)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180218
[Lr] Data última revisão:
180218
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171209
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0188807


  6 / 21827 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29351298
[Au] Autor:Noyce RS; Lederman S; Evans DH
[Ad] Endereço:Department of Medical Microbiology & Immunology and Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta, Canada.
[Ti] Título:Construction of an infectious horsepox virus vaccine from chemically synthesized DNA fragments.
[So] Source:PLoS One;13(1):e0188453, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Edward Jenner and his contemporaries believed that his variolae vaccinae originated in horses and molecular analyses show that modern vaccinia virus (VACV) strains share common ancestry with horsepox virus (HPXV). Given concerns relating to the toxicity of modern VACV vaccines, we asked whether an HPXV-based vaccine might provide a superior alternative. Since HPXV may be extinct and the only specimen of HPXV that has been identified is unavailable for investigation, we explored whether HPXV could be obtained by large-scale gene synthesis. Ten large (10-30 kb) fragments of DNA were synthesized based on the HPXV sequence along with two 157 nt VACV terminal sequences, and were recombined into a live synthetic chimeric HPXV (scHPXV) in cells infected with Shope fibroma virus (SFV). Sequencing of the 212 kbp scHPXV confirmed it encoded a faithful copy of the input DNA. We believe this is the first complete synthesis of a poxvirus using synthetic biology approaches. This scHPXV produced smaller plaques, produced less extracellular virus and exhibited less virulence in mice than VACV, but still provided vaccine protection against a lethal VACV challenge. Collectively, these findings support further development of scHPXV as a novel replication-proficient smallpox vaccine.
[Mh] Termos MeSH primário: DNA/química
Orthopoxvirus/imunologia
Vacinas Sintéticas/imunologia
Vacinas Virais/imunologia
[Mh] Termos MeSH secundário: Administração Intranasal
Animais
Cercopithecus aethiops
Células HeLa
Seres Humanos
Camundongos
Orthopoxvirus/crescimento & desenvolvimento
Orthopoxvirus/patogenicidade
Vacinas Sintéticas/administração & dosagem
Células Vero
Vacinas Virais/administração & dosagem
Virulência
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Vaccines, Synthetic); 0 (Viral Vaccines); 9007-49-2 (DNA)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180120
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0188453


  7 / 21827 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29351277
[Au] Autor:Hammami P; Lancelot R; Domenech J; Lesnoff M
[Ad] Endereço:UMR 117 Animals, Health, Territories, Risks and Ecosystems (ASTRE), Centre de coopération internationale en recherche agronomique pour le développement (CIRAD), Campus international de Baillarguet, 34398 Montpellier, France.
[Ti] Título:Ex-ante assessment of different vaccination-based control schedules against the peste des petits ruminants virus in sub-Saharan Africa.
[So] Source:PLoS One;13(1):e0190296, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Peste des petits ruminants (PPR) is a highly contagious and widespread viral infection of small ruminants (goats and sheep), causing heavy economic losses in many developing countries. Therefore, its progressive control and global eradication by 2030 was defined as a priority by international organizations addressing animal health. The control phase of the global strategy is based on mass vaccination of small ruminant populations in endemic regions or countries. It is estimated that a 70% post-vaccination immunity rate (PVIR) is needed in a given epidemiological unit to prevent PPR virus spread. However, implementing mass vaccination is difficult and costly in smallholder farming systems with scattered livestock and limited facilities. Regarding this, controlling PPR is a special challenge in sub-Saharan Africa. In this study, we focused on this region to assess the effect of several variables of PVIR in two contrasted smallholder farming systems. METHODS: Using a seasonal matrix population model of PVIR, we estimated its decay in goats reared in sub-humid areas, and sheep reared in semi-arid areas, over a 4-year vaccination program. Assuming immunologically naive and PPR-free epidemiological unit, we assessed the ability of different vaccination scenarios to reach the 70% PVIR throughout the program. The tested scenarios differed in i) their overall schedule, ii) their delivery month and iii) their vaccination coverage. RESULTS: In sheep reared in semi-arid areas, the vaccination month did affect the PVIR decay though it did not in goats in humid regions. In both cases, our study highlighted i) the importance of targeting the whole eligible population at least during the two first years of the vaccination program and ii) the importance of reaching a vaccination coverage as high as 80% of this population. This study confirmed the relevance of the vaccination schedules recommended by international organizations.
[Mh] Termos MeSH primário: Doenças das Cabras/prevenção & controle
Esquemas de Imunização
Peste dos Pequenos Ruminantes/prevenção & controle
Vírus da Peste dos Pequenos Ruminantes/imunologia
Doenças dos Ovinos/prevenção & controle
Vacinas Virais/administração & dosagem
[Mh] Termos MeSH secundário: África ao Sul do Saara
Animais
Cabras
Ovinos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Viral Vaccines)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180120
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0190296


  8 / 21827 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28464951
[Au] Autor:Elberry MH; Darwish NHE; Mousa SA
[Ad] Endereço:The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY, 12144, USA.
[Ti] Título:Hepatitis C virus management: potential impact of nanotechnology.
[So] Source:Virol J;14(1):88, 2017 05 02.
[Is] ISSN:1743-422X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Around 170-200 million individuals have hepatitis C virus (HCV), which represents ~ 3% of the world population, including ~ 3-5 million people in the USA. According to the WHO regional office in the Middle East, Egypt has the highest prevalence in the world, with 7% prevalence in adults. There had been no effective vaccine for HCV; a combination of PEG-Interferon and ribavirin for at least 48 weeks was the standard therapy, but it failed in more than 40% of the patients and has a high cost and serious side effects. The recent introduction of direct-acting antivirals (DAA) resulted in major advances toward the cure of HCV. However, relapse and reduced antiviral efficacy in fibrotic, cirrhotic HCV patients in addition to some undesired effects restrain the full potential of these combinations. There is a need for new approaches for the combinations of different DAA and their targeted delivery using novel nanotechnology approaches. In this review, the role of nanoparticles as a carrier for HCV vaccines, anti-HCV combinations, and their targeted delivery are discussed.
[Mh] Termos MeSH primário: Sistemas de Liberação de Medicamentos/métodos
Hepacivirus/imunologia
Hepatite C Crônica/tratamento farmacológico
Hepatite C Crônica/prevenção & controle
Nanotecnologia/métodos
[Mh] Termos MeSH secundário: Antivirais/uso terapêutico
Quimioterapia Combinada
Genótipo
Hepacivirus/genética
Hepatite C Crônica/imunologia
Hepatite C Crônica/virologia
Seres Humanos
MicroRNAs/farmacologia
Nanopartículas/virologia
Ribavirina/uso terapêutico
Vacinas Virais/química
Vacinas Virais/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antiviral Agents); 0 (MicroRNAs); 0 (Viral Vaccines); 49717AWG6K (Ribavirin)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170504
[St] Status:MEDLINE
[do] DOI:10.1186/s12985-017-0753-1


  9 / 21827 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28454913
[Au] Autor:You SH; Kim T; Choi JH; Park G; Lee KN; Kim B; Lee MH; Kim HS; Kim SM; Park JH
[Ad] Endereço:Foot-and-Mouth Disease Vaccine Research Center, Animal and Plant Quarantine Agency, 177 Hyeoksin 8-ro, Gimcheon-City, Gyeongsangbuk-do, Republic of Korea; Veterinary College of Chungnam National University, 99 Daehak-ro, Yuseong-gu, Daejeon, Republic of Korea.
[Ti] Título:Coinjection of a vaccine and anti-viral agents can provide fast-acting protection from foot-and-mouth disease.
[So] Source:Antiviral Res;143:195-204, 2017 07.
[Is] ISSN:1872-9096
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Foot-and-mouth disease (FMD) is the cause of an economically devastating animal disease. With commercial inactivated FMD vaccines, the protection against FMD virus (FMDV) begins a minimum of 4 days post vaccination (dpv). Therefore, antiviral agents could be proposed for rapid protection and to reduce the spread of FMDV during outbreaks until vaccine-induced protective immunity occurs. In previous studies, we have developed two recombinant adenoviruses that simultaneously express porcine interferon-α and interferon-γ (Ad-porcine IFN-αγ) and multiple siRNAs that target the non-structural protein-regions of FMDV (Ad-3siRNA), and we have shown that the combination of the two antiviral agents (referred to here as Ad combination) induced robust protection against FMDV in pigs. In an attempt to provide complete protection against FMDV, we co-administered Ad combination and the FMD vaccine to mice and pigs. In the C57BL/6 mice model, we observed rapid and continuous protection against homologous FMDV challenge from 1 to 3 dpv-the period in which vaccine-mediated immunity is absent. In the pig experiments, we found that most of the pigs (five out of six) that received vaccine + Ad combination and were challenged with FMDV at 1 or 2 dpv were clinically protected from FMDV. In addition, most of the pigs that received vaccine + Ad combination and all pigs inoculated with the vaccine only were clinically protected from an FMDV challenge at 7 dpv. We believe that the antiviral agent ensures early protection from FMDV, and the vaccine participates in protection after 7 dpv. Therefore, we can say that the combination of the FMD vaccine and effective antiviral agents may offer both fast-acting and continuous protection against FMDV. In further studies, we plan to design coadministration of Ad combination and novel vaccines.
[Mh] Termos MeSH primário: Antivirais/farmacologia
Vírus da Febre Aftosa/efeitos dos fármacos
Febre Aftosa/prevenção & controle
Vacinação
Vacinas Virais/farmacologia
[Mh] Termos MeSH secundário: Adenoviridae/genética
Animais
Anticorpos Neutralizantes
Anticorpos Antivirais/imunologia
Antivirais/administração & dosagem
Citocinas/sangue
Combinação de Medicamentos
Vírus da Febre Aftosa/patogenicidade
Células HEK293
Seres Humanos
Injeções Intramusculares
Interferon-alfa/farmacologia
Interferon gama/farmacologia
Camundongos
Camundongos Endogâmicos C57BL
RNA Interferente Pequeno/farmacologia
Recombinação Genética
Taxa de Sobrevida
Suínos
Vacinas de Produtos Inativados/farmacologia
Proteínas não Estruturais Virais/imunologia
Vacinas Virais/administração & dosagem
Vacinas Virais/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antibodies, Neutralizing); 0 (Antibodies, Viral); 0 (Antiviral Agents); 0 (Cytokines); 0 (Drug Combinations); 0 (Interferon-alpha); 0 (RNA, Small Interfering); 0 (Vaccines, Inactivated); 0 (Viral Nonstructural Proteins); 0 (Viral Vaccines); 82115-62-6 (Interferon-gamma)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170430
[St] Status:MEDLINE


  10 / 21827 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27779467
[Au] Autor:Meltzer E; Paran Y; Lustig Y; Stienlauf S; Weinberger M; Schwartz E
[Ti] Título:Travel-Related Tick-Borne Encephalitis, Israel, 2006-2014.
[So] Source:Emerg Infect Dis;23(1):119-121, 2017 01.
[Is] ISSN:1080-6059
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:During 2006-2014, four tick-borne encephalitis (TBE) cases occurred among Israeli travelers. We calculated TBE incidence at 321.0, 45.0, 13.2, and 7.5 cases/100,000 travelers/year of travel to Sweden, Switzerland, Austria, and Germany, respectively. TBE incidence among travelers to these destinations appears to justify TBE vaccination in accordance with World Health Organization recommendations.
[Mh] Termos MeSH primário: Vetores Aracnídeos/virologia
Encefalite Transmitida por Carrapatos/epidemiologia
Encefalite Transmitida por Carrapatos/transmissão
Carrapatos/virologia
Viagem
[Mh] Termos MeSH secundário: Animais
Áustria/epidemiologia
Vírus da Encefalite Transmitidos por Carrapatos/patogenicidade
Vírus da Encefalite Transmitidos por Carrapatos/fisiologia
Encefalite Transmitida por Carrapatos/prevenção & controle
Alemanha/epidemiologia
Seres Humanos
Incidência
Israel/epidemiologia
Suécia/epidemiologia
Suíça/epidemiologia
Vacinação
Vacinas Virais/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Viral Vaccines)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180209
[Lr] Data última revisão:
180209
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE
[do] DOI:10.3201/eid2301.160888



página 1 de 2183 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde